"For a topical solution drug product, in vivo bioequivalence may be waived if the inactive ingredients in the product are qualitatively (Q1 ) identical and quantitatively (Q2 ) essentially the same compared to the listed drug. In this setting, quantitatively essentially the same means that the amount/concentration of the inactive ingredient(s) in the test product cannot differ by more than + 5 percent of the amount/concentration of the listed drug. Where a test solution differs in Q1 and/or Q2 from the listed drug, in vivo BE may be waived, provided the sponsor submits evidence that the difference does not affect safety and/or efficacy of the product at the time a waiver is requested." Quoted from FDA draft guidance "Topical Dermatological Drug Product NDAs and ANDAs - In Vivo Bioavailability, Bioequivalence, In Vitro Release, and Associated Studies. The last sentence says that in vivo BE may be waived if Q1 and/or Q2 are different from RLD, but sponsor must submit evidence that difference doesn’t affect safety and/or efficacy. What are some examples of evidence that the FDA would be looking for to verify safety and/or efficacy?

More Ramon Verduzco's questions See All
Similar questions and discussions